Last reviewed · How we verify

Miller Orthopedic Specialists — Portfolio Competitive Intelligence Brief

Miller Orthopedic Specialists pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ε-Aminocaproic Acid (EACA) ε-Aminocaproic Acid (EACA) marketed Antifibrinolytic Plasminogen and plasmin Other
bupivacaine HCl, morphine, epinephrine, methylprednisolone bupivacaine HCl, morphine, epinephrine, methylprednisolone marketed

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. German Heart Center · 1 shared drug class
  4. Institut Kassab d'Orthopédie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Miller Orthopedic Specialists:

Cite this brief

Drug Landscape (2026). Miller Orthopedic Specialists — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/miller-orthopedic-specialists. Accessed 2026-05-17.

Related